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Abstract
Children with perinatally acquired HIV-1 infection are surviving into adolescence and increasingly transitioning
toward adult services. Planning appropriate services in adult life requires an understanding of their progress
through pediatric care. We describe the demographic features, disease progression, antiretroviral therapy (ART),
and resistance in young people aged 10 years or more living in the United Kingdom and Ireland reported to the
National Study of HIV in Pregnancy and Childhood (NSHPC) with prospective annual follow-up in the Col-
laborative HIV Paediatric Study (CHIPS) between 1996 and September 2007. Six hundred fifty-four perinatally
infected young people were identified; 76% black African, 57% born abroad. Median age at presentation and
duration of follow-up was 1 and 11 years, respectively, if born in the United Kingdom=Ireland, and 8 and 5 years
if born elsewhere. One hundred sixty-nine (26%) ever had an AIDS-defining illness. Ten died during adoles-
cence. At last follow-up, 64% were on ART, 18% off treatment having previously received ART and 18% were
ART naive. Of 518 who had received highly active antiretroviral therapy (HAART), 47% were triple class
experienced. At last follow-up 77 (12%) had CD4 counts less than 200 per microliter; of those on HAART, 78%
had HIV-1 RNA 400 copies per milliliter, median CD4 count 554 (interquartile range [IQR] 324–802). Among
166 with resistance assays on HAART, 52% and 12% had dual- and triple-class HIV-1–associated resistance
mutations, respectively. One hundred three (16%) young people had transferred to adult services. Young adults
with perinatally acquired HIV-1 infection require coordinated multidisciplinary transitional care services and
careful long-term follow-up in adult life.
Introduction
In Europe, prior to the availability of antiretroviral therapy(ART), half of HIV-infected children died by their tenth
birthday and the majority of survivors were symptomatic.1
The introduction of highly active antiretroviral therapy
(HAART) in 1996 has resulted in a substantial increase in
life expectancy for adults with HIV infection living in high-
income countries.2,3 Additionally, in pediatric populations,
HAART has been associated with a substantial reduction in
HIV-associated mortality and morbidity.4–6
Consequently, children with perinatally acquired HIV in-
fection are now surviving into adolescence and early adult life
and increasingly transitioning from pediatric to adult ser-
vices. While transitional care for adolescents with HIV is an
emerging specialty, much can be learned from the experiences
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2MRC Clinical Trials Unit, London, United Kingdom.
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of other specialties caring for young people surviving with
chronic diseases of childhood in establishing optimal care
pathways. Studies have shownpoor attendance andadherence
among some cohorts of young people surviving other chronic
conditions of childhood, including cystic fibrosis, diabetes, and
congenital heart disease, resulting in increased morbidity and
mortality following transfer to adult services.7–10 Initial data
suggest poorer adherence to ART resulting in lower rates of
virologic suppression in HIV-infected adolescents compared
with younger pediatric and adult cohorts.11,12 Additionally,
younger age is associated with lower rates of uptake of out-
patient care in adults with sexually acquired HIV and there
are already concerns regarding attendance rates in young
people with perinatally acquired HIV following transfer to
adult services.13,14 In recognition of the poor service provision
for adolescents with severe chronic diseases the Department
of Health in the United Kingdom has clear guidelines re-
commending pathways to facilitate optimal transitional care
across all specialties15 andHIV specific guidelines are available
from the Children’s HIV Association.16
Planning future service provision for young adults with
perinatally acquired HIV infection requires an understanding
of their progression through pediatric care. We describe the
mortality, morbidity, immunologic, and virologic responses
to antiretroviral therapy and HIV-1–associated resistance
mutations in a cohort of verticallyHIV-infected young people,
surviving into adolescence and transitioning toward adult
services in the United Kingdom or Ireland.
Methods
Study design
The Collaborative HIV Paediatric Study (CHIPS) has been
described indetail elsewhere.4 Briefly, all childrenwith known
perinatal exposure to HIV, or diagnosed with HIV under the
age of 16 in the UK or Ireland, are reported to the National
Study of HIV in Pregnancy and Childhood (NSHPC). De-
tailed clinical, laboratory, and treatment information is then
collected annually through CHIPS for almost all (>90% by
2007) infected infants and children. By September 30, 2007,
1313 vertically infected children had been included in CHIPS,
of whom 654 were aged 10 years or older at last report (96%
seen in 2005–2007) and comprise the cohort analyzed here.
CHIPS and theNSHPC have ethics approval from the London
MREC, including approval for linkage with the U.K. HIV
Drug Resistance Database.
Statistical methods
All analyses were conducted using Stata 9 (Stata Corp,
College Station, TX). Demographic differences were explored
using descriptive statistics, with particular focus on place of
birth, age at and year of presentation, and age at last follow-
up. Proportions were compared using w2 tests, and medians
and means were compared using two-sampleWilcoxon rank-
sum tests and t tests, respectively. HAART was defined as
three or more antiretroviral drugs from two ormore classes or
a nucleoside reverse transcriptase inhibitor (NRTI) regimen
containing abacavir. Clinical events were defined according
to the Centers for Disease Control classification system.17
Weight and height z scores were compared to normative U.K.
data18with severe growth retardation defined as aweight-for-
age and=or height-for-age z-score less than 2.
Resistance test results were obtained by matching the
CHIPS cohort to the U.K. HIV Drug Resistance Database,
using a combination of hospital number, hospital of care, date
of birth, and patient initials. Multiple results for a single in-
dividual are presented as cumulative mutations.19 Resistance
was defined as one or more major mutations as specified in
the latest IAS-USA guidelines,20 plus selected additional
mutations (in reverse transcriptase, any mutation at G190 or
T215; in protease, V32I and I47V=A in combination, or seven
or more minor lopinavir mutations). As in other analyses,19
because the lamivudine=FTC-associated M184V mutation
confers no significant resistance to other NRTIs it was con-
sidered as a fourth class of mutation.
Results
Demographic characteristics
Table 1 shows the demographic characteristics of the 654
young people aged 10 years or older at last follow-up, by age
at last follow-up and country of birth. Just over half (53%)
were female, three quarters (76%) were black African, and
57% were born abroad. Sixty percent of those born in the
U.K.=Ireland were of black African origin, compared to 88%
of those born abroad (v22, p< 0.001). Age at presentation
differed by place of birth: median age at presentation of those
born in the U.K.=Ireland was 1 year, compared to 8 years for
those born abroad ( p< 0.001), and the median duration of
follow-upwas 11 and 5 years, respectively ( p< 0.001). Almost
a quarter (22%) of children born in the U.K.=Ireland were
identified prospectively from birth compared to 2.5% of those
born abroad, while the proportion identified on screening
following the diagnosis of a family member was higher in
those born abroad (41% and 31%, respectively, v25, p< 0.001).
AIDS diagnoses and mortality
Aquarter (169, 26%) had ever had an AIDS diagnosis (CDC
stage C). Sixty-one (9%) presented with AIDS, but there was
no difference by age at presentation (9% for less than 10 years
versus 12% for 10 or more years, w21, p¼ 0.234). A third (32%,
90) of those born in the U.K.=Ireland had been diagnosedwith
at least one AIDS defining illness, compared with 24% (89) of
those born elsewhere (w21, p¼ 0.030). AIDS diagnoses for the
whole cohort included Pneumocystis carinii pneumonia=
cytomegalovirus (PCP=CMV; 6%, 41), other opportunistic
infections (7%, 48), failure to thrive (11%, 70), serious recur-
rent bacterial infections (10%, 67), HIV encephalopathy (4%,
26) and cancer (2%, 11).
Ten children died after their tenth birthday (Table 2), of
whom nine were born abroad and five first presented prior to
the introduction of HAART in 1997. Six were aged 10 years or
older at presentation, five had relatively short follow up pe-
riods (<13 months) until death, and for six CD4 count prior to
death was less than 200 cells per milliliter. Nine died of causes
attributable to HIV infection, and the tenth died with pan-
creatitis while on a HAART combination, which included
stavudine and didanosine.
Antiretroviral therapy
Overall, at last follow-up, almost one in five (18%, 117)
young people had never received ART (Fig. 1). ART initiation
differed by age at presentation: nearly a quarter (24%, 35=143)
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of those presenting at age 10 years or older remained ART
naive, compared to 16% (82=511) of those presenting 10 years
or younger (w21, p¼ 0.020). Nineteen had only receivedmono-
or dual ART regimens, of whom nine were still in active
follow-up in 2005–2007: of these, only one remained on dual
therapy, with eight having stopped all ART. The remaining
children were lost to follow up (4), had transferred to adult
care (5), or had died (1).
Of the 518 adolescents who had received three or four drug
ART (HAART), 29% (149) started on mono- or dual therapy,
most (89%) prior to 1998, transferring to HAART a median of
2 years (IQR 1.2–4.7) later. Three quarters (78%, 396) of those
starting HAART were still receiving HAART at last follow-
up, 19% (100) had stopped all ART, and 3%were on mono- or
dual regimens. Reasons for stopping HAART included poor
compliance=child refusal (49), structured treatment interrup-
tion (25), and other (26).
The composition of initial HAART regimens changed over
time: prior to 2000, two thirds (67%) of initial HAART regi-
mens contained a protease inhibitor, most frequently nelfi-
navir (86%), and 33% an NNRTI, most commonly nevirapine
(91%). From 2003 onwards, 86% on initial regimens were
NNRTI-based, almost three quarters (73%) of which con-
tained efavirenz with all initial protease inhibitor-based
regimens (14%) containing ritonavir-boosted lopinavir. Ad-
ditionally, 66% of initial regimens prior to 2000 contained the
NRTI stavudine, declining to 9% for 2003 onwards. Half (47%)
of those who had ever received HAART were triple class
experienced; 85% had taken non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs) and 60% protease inhibitors
(PIs). Eight young people had ever taken the fusion inhibi-
tor enfuvirtide (T20), and six continued on this drug at last
follow-up. Prior to September 2007 no young person had re-
ceived an integrase or CCR5 inhibitor, or the newer genera-
tion PI darunavir or NNRTI etravirine.
Immunology and virology
Median CD4 count and percentage at HIV diagnosis
(at median [IQR] age 5 [0–16] years) were 540 cells per mi-
croliter (IQR 241–935) and 20% (IQR 12%–28%), respectively.
For those ever taking HAART (including those with previous
mono-=dual therapy) CD4 count was 250 per microliter and
percentage 13% (IQR 106–490, 6%–20%), respectively, at the
start of HAART (n¼ 518, median [IQR] age 9 (0.5–18) years),
increasing to 459 and 20% (IQR 268–770, 14%–28%) at 6
months, and 569 (IQR 343–830) and 25% (IQR 17%–31%) at 12
months. Fifty-eight percent achieved virologic suppression
400 copies or less per milliliter 6 months after HAART initi-
ation and 55% after 12 months. Of those on HAART at last
follow-up, 78% had a viral load 400 copies or less per milliliter
and median CD4 cell count and percentage were 555 per
microliter (IQR 324–802) and 27% (IQR 19%–34%), respec-
tively. Of those who remainedHAART naive at last follow-up
(117, median [IQR] age 13 [10–19] years), 7% had a viral load
400 copies or less per milliliter andmedian CD4 cell count and
percentage were 474 per microliter (IQR 330–600) and 23%
(IQR 17%–29%).
At last follow-up 77 (12%) young people had evidence of
severe immunosuppression (CD4 count <200 per microliter).
Fifty (70%)were onHAART, 13were off ART after previously
being on HAART, 7 were either ART-naive (3) or on mono-
therapy (3—atazanavir=ritonavir [1]; lopinavir=ritonavir [1];
ritonavir [1]) or dual therapy (2—tenofovir with atazanavir=
ritonavir [1]; tenofovir with lopinavir=ritonavir [1]) and 6 died
(see above).
Resistance
A total of 423 resistance test results were available for 211
(32%) of the 654 young people. The most common HIV sub-
types were C (77), A (49), B (26), and D (25).
Total
n=654
Remained ART naïve
n=117 (18%)
Commenced ART
n=537 (82%)
Initial mono/ dual
therapy n=168 (31%)
HAART
n=369 (69%)
Remained on
mono/
dual n=19 (11%)
Subsequent
HAART
n=149 (89%)
FIG. 1. Antiretroviral treatment history of vertically HIV-infected children in the United Kingdom and Ireland surviving
to age 10 years or more.
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Thirty-six of the 211 had baseline resistance testing of
whom 34 had wild-type virus and two had resistance muta-
tions (patient 1—62V, 65R, 106M, 115F, 184V; 2—41L, 74V,
184V, 190A, 210W, 215Y). A further 9 had a resistance test after
commencing mono- or dual therapy but prior to HAART; 4
had wild-type virus and 5 (56%) had resistance mutations
(TAMS [5] 184I [1], 69S [1]). Of the 7 patients with resistance
mutations, 5e had presented 2 years of age or older, and none
received mother–to-child prophylaxis.
One hunded sixty-six (79%) had their first resistance test
after the start of HAART, with a median of 3 years (IQR 1–5)
between HAART initiation and the first resistance assay.
Cumulative results indicated that 23 (14%) had wild-type
virus, 81 (49%) had M184I=V mutations, and 95 (57%) had
non-M184V NRTI mutations, most frequently TAMS (RT
positions 41L [48], 67N [46], 70R [28], 210W [31], 215any
[88], and 219E=Q [27]). One hundred eight (65%) had NNRTI-
associated mutations, most commonly 103N (55), 181C=I (45)
and 190A (27). Major protease mutations were detected in 43
(26%) children, most commonly 90M (19) and 46I=L (14).
One hundred thirty-eight (65%) of the 211 were triple class
experienced of whom 53% and 16% had dual- and triple-class
HIV-1–associated resistance mutations.
Growth
Mean height z score at first measurement was 0.8 (stan-
dard deviation [SD]¼ 1.3) from published norms18 and was
slightly lower among those first measured at age 10 years or
older compared to younger than 10 years (1.1, n¼ 160 versus
0.7, n¼ 489 respectively, p< 0.001). Similarly mean weight
z-score at first measurement was 0.5 (SD¼ 1.3), and was
marginally lower among those first measured at age 10 or
more compared to younger than 10 years (0.7, n¼ 159 versus
0.4, n¼ 493, respectively, p¼ 0.022). Sixteen (3%) of those
first measured at younger than 10 years had severe growth
retardation, and similarly 11 (9%) measured for the first time
at 10 years or older. At last growth measurement, 13 of 288
young people (5%) aged 13 had evidence of severe growth
retardation all of whom were on HAART.
Transfer to adult care
One hundred three (16%) of the young people had trans-
ferred to adult services by September 30, 2007, at amedian age
of 17 years (range, 15–22). They had been followed in CHIPS
for a median of 12 years (IQR 7–15), longer for those born in
the U.K.=Ireland (15 years [IQR 12–17]) than for those born
abroad (9 years [IQR.5–13]). Thirty-nine (38%) had ever had
anAIDS diagnosis by the time of transfer to adult care. Sixteen
were ART-naı¨ve at transfer and of the 82 who had ever re-
ceived HAART, half (52%) were triple-class experienced.
At point of transfer to adult services a quarter (28) had
evidence of severe immunosuppression (CD4 count <200
per microliter). Sixty were receiving HAART, for whom me-
dian CD4 count at last measurement was 318 per microli-
ter (IQR 179–576) and 33 (55%) had viral loads less than 400
copies per milliliter. Resistance test results were available
for 41 of the 103 young people, and 17 had dual- and 6 triple-
class resistance; 15 (65%) of the 23 with dual- or triple-class
resistance had prior mono-=dual therapy before starting
HAART.
Discussion
This study shows that children with perinatally acquired
HIV infection living in the United Kingdom or Ireland and
followed in the CHIPS cohort are not only surviving into
adolescence but also transferring to adult services. High up-
take of antenatal testing21 reduced transmission rates from
diagnosed women,22 improved survival following HAART
and later age at presentation among those born abroad6 mean
that the average age of perinatally infected children and
young people in the United Kingdom or Ireland continues to
rise, with half of the CHIPS cohort now aged 10 years or over.
By September 2007, 8% of the entire CHIPS cohort had al-
ready entered adult services. All of the 654 young people
described in this paper were aged 10 years or over at last
follow-up and therefore all will require adult services by the
end of 2015, assuming that transfer continues at a median age
of 17 years. Furthermore, this group will grow in size as ad-
ditional young people are newly diagnosed in adolescence
over the coming years. Recent studies illustrate the accept-
ability and feasibility of HIV screening for adolescents within
the emergency department23 and the promotion screening all
offspring of adults living with HIV24 may further enhance
diagnoses in adolescence. Over one fifth of this cohort was
initially diagnosed aged over 10 years, the majority of whom
were born abroad. The current trend for dispersal of migrants
throughout the United Kingdom will increase the number of
health professionals caring for young adults with perinatally
acquired HIV.
Many young people in this cohort have complex treatment
histories, with four fifths (79%) having been exposed to
HAART, with disappointing levels of viral suppression over-
all. This may be accounted for, in part, by unavoidable prior
exposure to suboptimal mono- and dual therapy in the pre-
HAART era, seen in a third of this cohort. Additionally,
suboptimal adherence during the turbulent period of ado-
lescence25 is well recognized both in HIV and other chronic
diseases26,27 resulting in impaired response to treatment with
increased morbidity and mortality. Almost one tenth of the
young people who had ever started HAART were currently
off therapy due to poor adherence=refusal. In young people
with poor adherence, the balance between maintaining cur-
rent immunologic function and clinical health, against the risk
of acquisition of resistance mutations on failing regimens that
will limit future treatment options is complex. In a U.S. study,
almost two thirds of adolescents maintained on initial non-
suppressive HAART regimens developed drug resistance
mutations and this was more likely to occur on NNRTI- than
protease inhibitor-based HAART, and may influence pre-
scribing in naive patients.28
Maintaining adherence is particularly difficult in an ado-
lescent population on HAART, half of whom are triple-class
experienced and often do not have once-daily low pill burden
options available. Half of those who had ever taken HAART
were triple-class experienced, and of those who had resistance
assays two thirds had evidence of dual- or triple-class resis-
tance. Some young people will therefore require new agents,
both in existing as well as novel classes of ART,29 highlighting
the need for equal access to new therapies and adequate phar-
macokinetic data for pediatric and adolescent populations
when compared to adult populations. Baseline resistance
testing prior to HAART is of increasing importance in a
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population, many of whom are born in sub-Saharan Africa
and following the successful role out of ART may have re-
ceived, but be unable to give a history of, antiretroviral agents
either in earlier childhood or perinatally in the prevention of
mother to child transmission of HIV. Reassuringly, albeit with
need for improvement, 78% of young people in the cohort
currently on HAART had a viral load below 400 copies per
milliliter with good immune reconstitution (median CD4 555
per microliter) with rates of virologic suppression compara-
ble or better than those reported in perinatally infected co-
horts of children and adolescents from Europe and the United
States.30,31 Research on new strategies for giving HAART
need evaluating, including various forms of structured treat-
ment breaks in older children and adolescents, aimed at
maximizing adherence and efficacy while on HAART, at the
same time minimizing risk of any disease progression or de-
velopment of resistance.
Future adolescentswith perinatally acquiredHIVwho start
HAARTwith no previous ART exposure are expected to have
better virologic control. However, the duration of therapy
may be longer, particularly in light of recent evidence sup-
porting earlier initiation of HAART both in infants32 and
adults.33,34 While the medium- and long-term side effects of
ART are increasingly recognized in adult populations,35 a
limitation of this paper is the lack of toxicity data in a popu-
lation widely exposed to ART throughout postnatal growth
and development. This is currently being addressed in CHIPS
by prospective data collection on lipodystrophy, lipid pro-
files, bone density, and pubertal development. However,
follow-up in CHIPS ceases when adolescents transfer to adult
services and so discussions are underway as to how best to
facilitate long-term data collection in this important co-
hort, with key research areas including growth and puberty,
ART-related toxicity, disease progression, fertility, second-
generation mother-to-child transmission, and neurologic and
psychosocial functioning. The lack of neurodevelopmental
and psychosocial data, including the impact of adolescence on
adherence, is an important limitation of the study in a pop-
ulation by definition born into a family living with HIV. Some
of the young people will have lost parents to HIV-related
disease, half were born outside the United Kingdom, and the
majority are from diverse ethnic minority backgrounds.36 In
addition, while the impact of HIV-associated encephalopathy
in infancy resulting in hypertonic diplegia and early cognitive
impairment on mobility and employment in adult life may be
predicted37 more widespread data on neurocognitive func-
tioning, education and, increasingly as the cohort age, em-
ployment, are required.
Conclusion
The success of HAART has seen perinatally acquired HIV
become a chronic disease of childhood. Increasing numbers of
young people living with HIVwill transfer to adult services in
the United Kingdom or Ireland during the next decade. The
varied and complex needs of these young people must be met
by the development of multidisciplinary transitional care
services between pediatric and adult health care providers.
The legacy of their pediatric care will continue to impact in
adult life and careful long-term follow-up of this unique co-
hort is required to improve outcomes for young people with
HIV in the future.
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